A Review of Ixekizumab, an Anti-Interleukin-17A Monoclonal Antibody, for Moderate-to-Severe Plaque Psoriasis.
Psoriasis is a multifactorial chronic skin disease that can have significant detrimental effects on patients' physical, mental, antibodypsychosocial wellbeing. Patients often suffer from a decreased quality of life along with numerous comorbidities. Recent advances in our understanding of the innate and adaptive immune systems have led to the identification of interleukin (IL)-17 as a key pro-inflammatory mediator in psoriasis. This knowledge has in turn led to the development of newer biologic agents that have been shown to be more effective than traditional therapies. In this article, we review phase 1-3 clinical trials of the anti-IL-17 monoclonal antibody, ixekizumab, for treatment of moderate-to-severe plaque psoriasis.
Center for Clinical Studies, Houston, TX, USA.
A J
AJ
Peranteau
Baylor College of Medicine, Houston, TX, USA.
A E
AE
Turkeltaub
Department of Dermatology, University of California San Diego, San Diego, CA, USA.
Y
Y
Tong
Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA.
Z
Z
Nawas
Center for Clinical Studies, Houston, TX, USA; Department of Dermatology, University of Texas Health Science Center at Houston, Houston, TX, USA.
S K
SK
Tyring
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003879:Dermatologic Agents / Q000627:therapeutic use*; D006801:Humans; D020381:Interleukin-17 / Q000037:antagonists & inhibitors*; D011565:Psoriasis / Q000188:drug therapy*
D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D020381:Interleukin-17; C549079:ixekizumab